Skip to content

Kyverna Therapeutics, Inc. KYTX Balance Sheet Statement

FY'25FY'24FY'23
$124.09M+28.4%$96.62M+179%$34.65M
$155.16M-18.1%$189.36M+727%$22.9M
$282.95M-2.6%$290.6M+379%$60.66M
$1.55M-53.8%$3.35M+43.9%$2.33M
$293.83M-3.6%$304.65M+305%$75.2M
$26.71M-0.6%$26.87M+392%$5.46M
$307K-60.6%$779K-18.5%$956K
$36.49M+8.1%$33.76M+70.0%$19.86M
$61.55M+61.7%$38.06M+46.3%$26.02M
$1K$0
-$424.83M-61.2%-$263.52M-93.7%-$136.04M
$232.28M-12.9%$266.59M+2,129%-$13.14M+82.2%
$293.83M-3.6%$304.65M+305%$75.2M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Kyverna Therapeutics, Inc.'s total assets?
Kyverna Therapeutics, Inc. (KYTX) holds $257.0M in total assets, down 1.4% year over year.
How much debt does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. carries $9.2M in total debt against $195.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
How much cash does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. holds $32.2M in cash and equivalents.
Can Kyverna Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 8.15 — current assets exceed current liabilities.
Where does Kyverna Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.